Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/27514
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGrigoriadis G.en
dc.contributor.authorBanerjee A.en
dc.contributor.authorVasanthakumar A.en
dc.date.accessioned2021-05-14T09:15:46Zen
dc.date.available2021-05-14T09:15:46Zen
dc.date.copyright2013en
dc.date.created20130613en
dc.date.issued2013-06-13en
dc.identifier.citationImmunology and Cell Biology. 91 (5) (pp 340-349), 2013. Date of Publication: May-June 2013.en
dc.identifier.issn0818-9641en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/27514en
dc.description.abstractRegulatory T cells (Tregs) are a specialized subset of CD4 T cells that have an indispensable role in maintaining immune homeostasis and tolerance. Although studies in mice and humans have clearly highlighted that the absence of these cells results in severe autoimmunity and inflammation, increased Treg numbers and/or function is not always beneficial. This is best exemplified in certain cancers where increased Tregs promote cancer progression by interfering with immune surveillance. Conversely, in other types of cancers that have an inflammatory component, Tregs can inhibit cancer progression by dampening inflammation. In this review article, we provide a historical perspective of the discovery of Tregs, followed by a summary of the existing literature on the role of Tregs in malignancy. © 2013 Australasian Society for Immunology Inc. All rights reserved.en
dc.languageEnglishen
dc.languageenen
dc.publisherNature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom)en
dc.titleModulating T regulatory cells in cancer: How close are we?.en
dc.typeReviewen
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1038/icb.2013.12en
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid23567897 [http://www.ncbi.nlm.nih.gov/pubmed/?term=23567897]en
dc.identifier.source52530948en
dc.identifier.institution(Banerjee, Vasanthakumar, Grigoriadis) Centre for Inflammatory Diseases, Southern Clinical School, Monash University, Clayton, VIC 3168, Australia (Vasanthakumar) Molecular Immunology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia (Grigoriadis) Department of Clinical Haematology, Central Clinical School, Monash University, Clayton, VIC, Australia (Grigoriadis) Department of Clinical Haematology, Monash Health, Clayton, VIC, Australiaen
dc.description.addressA. Banerjee, Centre for Inflammatory Diseases, Southern Clinical School, Monash University, Clayton, VIC 3168, Australia. E-mail: ashish.banerjee@monash.eduen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2014 Elsevier B.V., All rights reserved.en
dc.subect.keywordscancer immunotherapy T regulatory cellsen
dc.identifier.authoremailBanerjee A.; ashish.banerjee@monash.edu Vasanthakumar A.; vasanthakumar@wehi.edu.au Grigoriadis G.; george.grigoriadis@monash.eduen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeReview-
crisitem.author.deptHaematology-
Appears in Collections:Articles
Show simple item record

Page view(s)

22
checked on Feb 6, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.